Functional frontal lobectomy in the surgical treatment of pharmacoresistant frontal lobe epilepsy: how I do it.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 39020068.
- Also identified by DOI 10.1007/s00701-024-06176-x and PMC identifier 11254979.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Frontal lobe epilepsy is pharmacoresistant in 30% of cases, constituting 10-20% of epilepsy surgeries. For cases of no lesional epilepsy (negative MRI), frontal lobectomy is a crucial treatment, historically involving Frontal Anatomical Lobectomy (AFL) with a 33.3% complication risk and 55.7% seizure control. We describe Frontal Functional Lobectomy (FFL), in which the boundaries are defined on the patient's functional cortico-subcortical areas, recognized with advanced intraoperative technologies such as tractography and navigated transcranial magnetic stimulation (nTMS). The FFL allows for a broader resection with a lower rate of postoperative complications than the AFL.
Medical subject headings
- Drug Resistant Epilepsy
- Epilepsy, Frontal Lobe
- Frontal Lobe